
    
      This study will be conducted by approximately 20 investigative sites in the U.S. and Poland.
      Participants who qualify will be randomized in equal proportions to receive either
      lansoprazole Pediatric Suspension (0.2-0.3 mg/kg/day in infants <10 weeks of age or 1.0-1.5
      mg/kg/day in infants >10 weeks of age) or Placebo. This study consists of three periods:
      Pretreatment Period of 7-14 days, Double-Blind Treatment Period of 4 weeks (Dosing), and the
      Post-Treatment Period of 30 days (Follow-Up).
    
  